Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Presatovir for RSV lower respiratory tract infection in hematopoietic cell transplant recipients
NL-OMON44425Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and pulmonary infection comparing Presatovir with Placebo (2 arms). Primary endpoint: Time-weighted average change in nasal RSV viral load from baseline to Day 9. Started Mar 2015; status: active, not recruiting.
02
Drugs
presatovir
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on NL-OMON44425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44425.